CERTIFICATION PURSUANT TO
                  18 USC, SECTION 1350, AS ADOPTED PURSUANT TO
             SECTIONS 302 AND 906 OF THE SARBANES-OXLEY ACT OF 2002


     In  connection  with  the Quarterly Report of Worldwide Medical Corporation
(the  "Company")  on  Form  10-QSB for the quarter ended September 30, 2002 (the
"Report"),  as  filed  with  the  Securities and Exchange Commission on the date
hereof, I, Daniel G. McGuire, Chief Executive Officer of the Company, certify to
the  best  of  my  knowledge,  pursuant  to  18 USC 1350, as adopted pursuant to
Sec.302 and promulgated as 18 USC 1350 pursuant to Sec.906 of the Sarbanes-Oxley
Act  of  2002,  that:

1.     The  Report  referenced  above  has  been  read  and  reviewed  by  the
undersigned.

2.     The Report fully complies with the requirements of Section 13(a) or 15(d)
of  the  Securities  Exchange  Act  of  1934.

3.     The  information contained in the Report fairly presents, in all material
respects,  the  financial  condition  and  result  of operations of the Company.

4.     Based upon my knowledge, the Report referenced above does not contain any
untrue  statement  of a material fact or omit to state a material fact necessary
in  order to make the statements made, in light of the circumstances under which
such  statements  were  made,  not  misleading.

5.     Based  upon  my  knowledge,  the  financial  statements,  and  other such
financial  information  included  in  the Report, fairly present in all material
respects the financial condition and results of operations of the Company as of,
and  for,  the  periods  presented  in  the  Report.

6.     I  acknowledge  that  I  and  the  Chief  Financial  Officer:

     A.  are  responsible  for establishing and maintaining "disclosure controls
and  procedures"  for  the  Company;

     B.  have  designed  such  disclosure controls and procedures to ensure that
material  information  is  made  known  to us, particularly during the period in
which  the  Report  was  being  prepared;

     C.  have  evaulated  the effectiveness of the Company's disclosure controls
and  procedures  within  90  days  of  the  date  of  the  Report;

     D.  have presented in the Report our conclusions about the effectiveness of
the  disclosure  controls  and  procedures  based  on  the  required evaluation;

     E.  have  disclosed  to the issuer's auditors and to the audit committee of
the  Board  of  Directors  of  the Company (or persons fulfilling the equivalent
function):

          (i)  all  significant  deficiencies  in  the  design  or  operation of
     internal  controls  which  could  adversely affect the Company's ability to
     record,  process,  summarize, and report financial data and have identified
     for  the  Company's  auditors any material weaknesses in internal controls;
     and

          (ii)  any  fraud, whether or not material, that involves management or
     other  employees  who  have  a  significant  role  in the issuer's internal
     controls;  and

     F.  have  indicated  in  the  Report  whether or not there were significant
changes in internal controls or in other factors that could significantly affect
internal  controls  subsequent  to  the  date  of  their  evaluation,  including
any corrective actions with regard  to  significant  deficiencies  and  material
weaknesses.



/s/  Daniel  G.  McGuire
____________________________________
Daniel  G.  McGuire
Chief  Executive  Officer
Dated:  November  18,  2002